People
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
GlaxoSmithKline Chief Executive Officer Emma Walmsley faces renewed calls for her ouster after Bluebell Capital Partners has taken a £10 million (about $13.7 million) stake in the company.
Aurion Biotech is focused on curative and restorative treatments for corneal endothelial disease.
MiroBio’s pipeline involves checkpoint receptor pathways, not for immuno-oncology indications, but for the treatment of autoimmune diseases.
Sheila Gujrathi, M.D. will join the board of directors as executive chair, while Jörn Drappa, M.D., Ph.D. will serve as chief medical officer.
Mirati Therapeutics tapped David Meek, the former chief executive officer of Ipsen, as its new CEO. He replaces company founder Charles Baum.
One constant throughout the conversation is that the industry is at a different stage of adapting to the “new normal.”
A trustee with the DOJ filed a request for an “expedited stay” in order to prevent the initiation of the bankruptcy plan.
The COVID-19 pandemic has changed science journalism. Semantics aside, though, science and health care have taken a new position in the hierarchy of top news priorities.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES